Friederike Kanefendt

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors

Paola Di Gion, Friederike Kanefendt, Andreas Lindauer et al. · Clinical Pharmacokinetics · 2011 · 214 citations

Medicinal Chemistry, Medicine, Clinical Pharmacokinetics +3

First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa

Dirk Thomas, Friederike Kanefendt, Stephan Schwers et al. · Journal of Thrombosis and Haemostasis · 2021 · 79 citations · Full text

Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple‐dose study

Dagmar Kubitza, Michael Heckmann, Jana Distler et al. · British Journal of Clinical Pharmacology · 2022 · 64 citations · Full text

Pharmacokinetic/Pharmacodynamic Modeling of Biomarker Response to Sunitinib in Healthy Volunteers

Andreas Lindauer, Paola Di Gion, Friederike Kanefendt et al. · Clinical Pharmacology & Therapeutics · 2010 · 54 citations

Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib‐Treated Cancer

Achim Fritsch, Friederike Kanefendt, JJ Swen et al. · CPT Pharmacometrics & Systems Pharmacology · 2017 · 31 citations · Full text

Active Drug Pks, First-line Therapy, Pharmacotherapy +18